Carina Biotech Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$7.5M
- Investors
-
5
Carina Biotech General Information
Description
Developer of a broad-spectrum chimeric antigen receptor T-cell technology designed to treat solid cancers, including pediatric and rare cancers. The company's platform develops T-cell therapy, which involves engineering a patient's own immune system to target and destroy their cancer cells, enabling doctors to use the therapy for the treatment of a broad range of cancers.
Contact Information
Website
www.carinabiotech.comCorporate Office
- Level 2, Ian Wark (IW) Building
- UniSA Mawson Lakes Campus
- Mawson Lakes, South Australia 5095
- Australia
Corporate Office
- Level 2, Ian Wark (IW) Building
- UniSA Mawson Lakes Campus
- Mawson Lakes, South Australia 5095
- Australia
Carina Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 14-Aug-2022 | $7.5M | Completed | Clinical Trials - Phase 1 | ||
| 6. Later Stage VC | 30-Aug-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 23-Apr-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Accelerator/Incubator | 01-Jan-2020 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 31-Jul-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 30-Jul-2018 | $1.7M | $1M | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | 20-Apr-2018 | $1M | $1M | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Carina Biotech Patents
Carina Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022903762-A0 | Methods for diagnosing and treating ovarian cancer | Inactive | 09-Dec-2022 | ||
| WO-2024119233-A1 | Methods for diagnosing and treating ovarian cancer | Inactive | 09-Dec-2022 | ||
| AU-2021900687-A0 | Methods for purifying t cells | Inactive | 10-Mar-2021 | ||
| AU-2020904256-A0 | Chimeric antigen receptor t cell and method | Inactive | 18-Nov-2020 | ||
| CA-3202371-A1 | Chimeric antigen receptor t cell and method | Pending | 18-Nov-2020 | A61K40/4202 |
Carina Biotech Signals
Carina Biotech Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Southern Angels | Angel Group | Minority | ||
| Tenmile | Venture Capital | Minority | ||
| Minderoo Foundation | Not-For-Profit Venture Capital | Minority | ||
| University of Adelaide Endowment | Limited Partner | |||
| Innovation and Collaboration Centre | Accelerator/Incubator |
Carina Biotech FAQs
-
When was Carina Biotech founded?
Carina Biotech was founded in 2016.
-
Where is Carina Biotech headquartered?
Carina Biotech is headquartered in Mawson Lakes, Australia.
-
What is the size of Carina Biotech?
Carina Biotech has 17 total employees.
-
What industry is Carina Biotech in?
Carina Biotech’s primary industry is Biotechnology.
-
Is Carina Biotech a private or public company?
Carina Biotech is a Private company.
-
What is Carina Biotech’s current revenue?
The current revenue for Carina Biotech is .
-
How much funding has Carina Biotech raised over time?
Carina Biotech has raised $12.4M.
-
Who are Carina Biotech’s investors?
Southern Angels, Tenmile, Minderoo Foundation, University of Adelaide Endowment, and Innovation and Collaboration Centre have invested in Carina Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process